Palvella Therapeutics (NASDAQ: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently in clinical development for microcystic lymphatic malformations (microcystic LMs) and cutaneous venous malformations. For more information, please go to www.palvellatx.com.
Company Details
- Employees
- 28
- Founded
- -
- Address
- 125 Strafford Ave,
- Phone
- (484) 253-1460
- in****@****atx.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- palvellatx.com
- HQ
- Wayne, PA
Palvella Therapeutics Questions
Palvella Therapeutics's helpline number is (484) 253-1460
Palvella Therapeutics's website is palvellatx.com
Palvella Therapeutics's LinkedIn profile is https://www.linkedin.com/company/palvella-therapeutics
Palvella Therapeutics has
28 employees.
View email and phone details for 28
employees at Palvella Therapeutics.
Palvella Therapeutics's industry is
Biotechnology Research
Palvella Therapeutics's top competitors are
Autobahn Therapeutics, Inc.,
Pieris Pharmaceuticals,
Madrigal Pharmaceuticals,
Mira Pharmaceuticals,
Incyte,
Acadia Pharmaceuticals Inc.,
Gilead Sciences,
Viking Therapeutics, Inc.,
Kbi Biopharma,
Ligand Pharmaceuticals.
Palvella Therapeutics's support email address is info@palvellatx.com
Palvella Therapeutics's categories are Biotechnology Research
Palvella Therapeutics's founding year is 2015
